Sunday, 18 January 2015

Cloud Management Solutions Assessment and Market Outlook 2015

Product Synopsis
This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents.

To get sample report with TOC Click Here:
The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar companies, and new technology providers as half-life prolongation technologies are no longer in the focus of major interest.
A short- to mid-term outlook into the field is provided and the trends driving the future of this therapeutic segment are identified and described. Preparation of this report is based on information stored in La Merie Publishing’s proprietary data base and news archive, on scientific literature, and on corporate disclosures. The data are presented, analyzed and assessed in a comprehensive manner by an experienced author with an independent view writing the fifth edition of this report series.
Benefits from the report:
Development of product sales and recombinant coagulation factors market
Sales performance of newly launched recombinant coagulation factors
Drug profiles for all relevant classical as well a semerging developments
Technologies, constructs and players in the gene therapy field of hemophilia
Alternative procoagulants: approaches, profiles, competitive advantages
Comparative analysis of key product features of new coagulation factors
Corporate profiles of all relevant stakeholders including deals and pipelines
Pipeline and technology trends
Table Of Content

1. Executive Summary
2. Recombinant Coagulation Factor Markets
2.1 Recombinant Factor VIII (rFVIII) Product Sales and Market Size
2.1.1 Advate/Recombinate Sales
2.1.2 Kogenate FS Sales
2.1.3 Helixate Sales
2.1.4 Xyntha / Refactor AF Sales
2.1.5 Eloctate Sales
2.1.6 2014 Performance of rFVIII Product Sales
2.1.7 rFVIII Market Size
2.2 Recombinant Factor IX (rFIX) Product Sales and Market Size
2.2.1 BeneFIX Sales
2.2.2 Alprolix Sales
2.2.3 2014 Performance of rFIX Product Sales
2.2.4 rFIX Market Size
2.3 Recombinant Factor VII (rFVII) Product Sales and Market Size
2.3.1 NovoSeven Sales
2.3.2 Coagil VII Sales
2.3.3 rFVII Market Size
2.4 Recombinant Thrombin Product Sales and Market Size
2.5 Total Recombinant Coagulation Factor Market Size
3. Pipeline Update of Recombinant Coagulation Factors
4. Competitive Landscape Analysis of Recombinant Coagulation Factors
5. Stakeholder Profiles
6. Strategic Analysis

Contact Us: 

For More Information Kindly Contact:
Website @
Get More Market Research Report :

No comments:

Post a Comment